{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T10:00:46Z","timestamp":1789898446067,"version":"4.0.1"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T00:00:00Z","timestamp":1778457600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005407","name":"Hong Kong Health Bureau","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005407","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100022720","name":"Health Bureau","doi-asserted-by":"publisher","award":["20211921"],"award-info":[{"award-number":["20211921"]}],"id":[{"id":"10.13039\/100022720","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["valuehealthregionalissues.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health Regional Issues"],"published-print":{"date-parts":[[2027,1]]},"DOI":"10.1016\/j.vhri.2026.101662","type":"journal-article","created":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T03:59:26Z","timestamp":1781668766000},"page":"101662","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Patient Preferences for Lipid-Lowering Agents in Hypercholesterolemia: A Discrete Choice Experiment"],"prefix":"10.1016","volume":"57","author":[{"given":"Hei Hang Edmund","family":"Yiu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent Ka Chun","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheri Cheuk Lam","family":"Au","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eunice Kehui","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin Chi Sang","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryan P.","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William Chi Wai","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sienna Yuxuan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun Ka","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther W.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph Edgar","family":"Blais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hung Fat","family":"Tse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos King Ho","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuxiao","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"32","key":"10.1016\/j.vhri.2026.101662_bib1","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1093\/eurheartj\/ehx144","article-title":"Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel","volume":"38","author":"Ference","year":"2017","journal-title":"Eur Heart J"},{"issue":"6","key":"10.1016\/j.vhri.2026.101662_bib2","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1093\/gerona\/glx169","article-title":"Adherence and persistence among statin users aged 65 years and over: a systematic review and meta-analysis","volume":"73","author":"Ofori-Asenso","year":"2018","journal-title":"J Gerontol: A, Biol Sci Med Sci"},{"issue":"8","key":"10.1016\/j.vhri.2026.101662_bib3","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.jacc.2016.06.005","article-title":"Assessing the impact of medication adherence on long-term cardiovascular outcomes","volume":"68","author":"Bansilal","year":"2016","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"10.1016\/j.vhri.2026.101662_bib4","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/S0022-3999(99)00057-4","article-title":"Patients\u2019 beliefs about prescribed medicines and their role in adherence to treatment in chronic physical illness","volume":"47","author":"Horne","year":"1999","journal-title":"J Psychosom Res"},{"issue":"12","key":"10.1016\/j.vhri.2026.101662_bib5","doi-asserted-by":"crossref","DOI":"10.2196\/42941","article-title":"Patient trust in physicians matters-understanding the role of a mobile patient education system and patient-physician communication in improving patient adherence behavior: field study","volume":"24","author":"Wu","year":"2022","journal-title":"J Med Internet Res"},{"issue":"8","key":"10.1016\/j.vhri.2026.101662_bib6","doi-asserted-by":"crossref","first-page":"661","DOI":"10.2165\/00019053-200826080-00004","article-title":"Conducting discrete choice experiments to inform healthcare decision making","volume":"26","author":"Lancsar","year":"2008","journal-title":"Pharmacoeconomics"},{"issue":"2","key":"10.1016\/j.vhri.2026.101662_bib7","doi-asserted-by":"crossref","DOI":"10.1111\/hex.14043","article-title":"Patient versus physician preferences for lipid-lowering drug therapy: a discrete choice experiment","volume":"27","author":"Zhang","year":"2024","journal-title":"Health Expect"},{"issue":"1","key":"10.1016\/j.vhri.2026.101662_bib8","article-title":"Reasons for non-acceptance of statin therapy by patients at high cardiovascular risk","volume":"15","author":"Xie","year":"2025","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.vhri.2026.101662_bib9","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1002\/clc.23935","article-title":"Nonadherence to lipid-lowering therapy and strategies to improve adherence in patients with atherosclerotic cardiovascular disease","volume":"46","author":"Desai","year":"2023","journal-title":"Clin Cardiol"},{"issue":"3","key":"10.1016\/j.vhri.2026.101662_bib10","doi-asserted-by":"crossref","first-page":"543","DOI":"10.14218\/JCTH.2021.00271","article-title":"Statin-induced liver injury patterns: a clinical review","volume":"10","author":"Averbukh","year":"2022","journal-title":"J Clin Transl Hepatol"},{"issue":"e1","key":"10.1016\/j.vhri.2026.101662_bib11","doi-asserted-by":"crossref","first-page":"e82","DOI":"10.1136\/ejhpharm-2022-003333","article-title":"Adverse drug reactions of statin therapy in China from 1989 to 2019: a national database analysis","volume":"30","author":"Tsui","year":"2023","journal-title":"Eur J Hosp Pharm"},{"key":"10.1016\/j.vhri.2026.101662_bib12","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.b92","article-title":"Association between change in high density lipoprotein cholesterol and cardiovascular disease morbidity and mortality: systematic review and meta-regression analysis","volume":"338","author":"Briel","year":"2009","journal-title":"BMJ"},{"key":"10.1016\/j.vhri.2026.101662_bib13","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.pcad.2024.10.009","article-title":"Revisiting high-density lipoprotein cholesterol in cardiovascular disease: is too much of a good thing always a good thing?","volume":"87","author":"Al Zein","year":"2024","journal-title":"Prog Cardiovasc Dis"},{"issue":"6","key":"10.1016\/j.vhri.2026.101662_bib14","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1097\/MOL.0000000000000896","article-title":"Strategies of improving adherence to lipid-lowering therapy in patients with atherosclerotic cardiovascular disease","volume":"34","author":"Karalis","year":"2023","journal-title":"Curr Opin Lipidol"},{"issue":"7","key":"10.1016\/j.vhri.2026.101662_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2023.e18256","article-title":"Discrete choice experiments: an overview on constructing D-optimal and near-optimal choice sets","volume":"9","author":"Alamri","year":"2023","journal-title":"Heliyon"},{"issue":"1","key":"10.1016\/j.vhri.2026.101662_bib16","first-page":"111","article-title":"ESC\/EAS Guidelines for the management of dyslipidemias: lipid modification to reduce cardiovascular risk: the Task Force for the management of dyslipidemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS)","volume":"41","author":"Mach","year":"2019","journal-title":"Eur Heart J. 2020"},{"issue":"10","key":"10.1016\/j.vhri.2026.101662_bib17","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1007\/s40273-024-01431-6","article-title":"A reporting checklist for discrete choice experiments in health: the DIRECT checklist","volume":"42","author":"Ride","year":"2024","journal-title":"Pharmacoeconomics"},{"issue":"1","key":"10.1016\/j.vhri.2026.101662_bib18","doi-asserted-by":"crossref","DOI":"10.1080\/20523211.2024.2421261","article-title":"Lipid-lowering agent preferences among patients with hypercholesterolemia: a focus group study","volume":"17","author":"Yiu","year":"2024","journal-title":"J Pharm Policy Pract"},{"issue":"5","key":"10.1016\/j.vhri.2026.101662_bib19","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s40271-015-0118-z","article-title":"Sample size requirements for discrete-choice experiments in healthcare: a practical guide","volume":"8","author":"de Bekker-Grob","year":"2015","journal-title":"Patient: Patient-Centered Outcomes Res"},{"issue":"3","key":"10.1016\/j.vhri.2026.101662_bib20","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1002\/hec.1369","article-title":"Rationalising the \u2018irrational\u2019: a think aloud study of discrete choice experiment responses","volume":"18","author":"Ryan","year":"2009","journal-title":"Health Econ"},{"key":"10.1016\/j.vhri.2026.101662_bib21","article-title":"An overview of data collection in health preference research","author":"Ozdemir","year":"2024","journal-title":"Patient: Patient-Centered Outcomes Res"},{"key":"10.1016\/j.vhri.2026.101662_bib23","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.2147\/PPA.S403252","article-title":"Factors influencing patient and caregiver preferences for antipsychotic treatment of schizophrenia in China: a discrete choice experiment","author":"Zhang","year":"2023","journal-title":"Patient Preference Adherence"},{"issue":"4","key":"10.1016\/j.vhri.2026.101662_bib24","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/s40273-018-0614-9","article-title":"Treatment preferences in Germany differ among apheresis patients with severe hypercholesterolemia","volume":"36","author":"M\u00fchlbacher","year":"2018","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.vhri.2026.101662_bib25","doi-asserted-by":"crossref","unstructured":"Reed SD, Sutphin J, Gonzalez JM, et al. Quantifying patient preferences about features of nonstatin lipid-lowering therapies: a discrete choice experiment in the United States. Circ Cardiovasc Qual Outcomes;18(8):e011804.","DOI":"10.1161\/CIRCOUTCOMES.124.011804"},{"issue":"9","key":"10.1016\/j.vhri.2026.101662_bib26","doi-asserted-by":"crossref","first-page":"618","DOI":"10.26599\/1671-5411.2023.09.007","article-title":"Chinese guideline for lipid management (2023): a new guideline rich in domestic elements for controlling dyslipidemia","volume":"20","author":"Li","year":"2023","journal-title":"J Geriatr Cardiol"},{"issue":"2","key":"10.1016\/j.vhri.2026.101662_bib27","first-page":"90","article-title":"Call to action: bridging gaps in lipid management in Hong Kong","volume":"30","author":"Yan","year":"2024","journal-title":"HK Med J"},{"issue":"1","key":"10.1016\/j.vhri.2026.101662_bib28","doi-asserted-by":"crossref","first-page":"9700","DOI":"10.1038\/s41598-021-89228-x","article-title":"Variations of risk factors for ischemic stroke and its subtypes in Chinese patients in Taiwan","volume":"11","author":"Tsai","year":"2021","journal-title":"Sci Rep"},{"issue":"2","key":"10.1016\/j.vhri.2026.101662_bib29","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1159\/000321734","article-title":"Trends in stroke incidence in Hong Kong differ by stroke subtype","volume":"31","author":"Chau","year":"2010","journal-title":"Cerebrovasc Dis"},{"key":"10.1016\/j.vhri.2026.101662_bib30","author":"Pignonne"},{"issue":"3","key":"10.1016\/j.vhri.2026.101662_bib31","doi-asserted-by":"crossref","first-page":"171","DOI":"10.2165\/11319380-000000000-00000","article-title":"Risk factors and drug interactions predisposing to statin-induced myopathy: implications for risk assessment, prevention and treatment","volume":"33","author":"Chatzizisis","year":"2010","journal-title":"Drug Saf"},{"key":"10.1016\/j.vhri.2026.101662_bib32","author":"Rosenson"},{"key":"10.1016\/j.vhri.2026.101662_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.pec.2023.107981","article-title":"Supporting older patients in making healthcare decisions: the effectiveness of decision aids; A systematic review and meta-analysis","volume":"116","author":"Gans","year":"2023","journal-title":"Patient Educ Couns"},{"key":"10.1016\/j.vhri.2026.101662_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajpc.2022.100430","article-title":"Earlier treatment in adults with high lifetime risk of cardiovascular diseases: what prevention trials are feasible and could change clinical practice? Report of a National Heart, Lung, and Blood Institute (NHLBI) workshop","volume":"12","author":"Navar","year":"2022","journal-title":"Am J Prev Cardiol"},{"issue":"7","key":"10.1016\/j.vhri.2026.101662_bib35","article-title":"Age group differences in the awareness of lifestyle factors impacting cardiovascular risk: a population-level study","volume":"15","author":"Okobi","year":"2023","journal-title":"Cureus"},{"issue":"8","key":"10.1016\/j.vhri.2026.101662_bib36","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCOUTCOMES.118.005562","article-title":"Sex differences in the use of statins in community practice","volume":"12","author":"Nanna","year":"2019","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"4","key":"10.1016\/j.vhri.2026.101662_bib37","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.jacl.2016.02.016","article-title":"Gender differences in side effects and attitudes regarding statin use in the Understanding statin Use in America and Gaps in Patient Education (USAGE) study","volume":"10","author":"Karalis","year":"2016","journal-title":"J Clin Lipidol"},{"issue":"2","key":"10.1016\/j.vhri.2026.101662_bib38","doi-asserted-by":"crossref","first-page":"458","DOI":"10.5114\/aoms\/157308","article-title":"Menopause and women\u2019s cardiovascular health: is it really an obvious relationship?","volume":"19","author":"Ryczkowska","year":"2023","journal-title":"Arch Med Sci"},{"issue":"1","key":"10.1016\/j.vhri.2026.101662_bib39","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s12910-023-00999-6","article-title":"Family roles in informed consent from the perspective of young Chinese doctors: a questionnaire study","volume":"25","author":"Xu","year":"2024","journal-title":"BMC Med Ethics"},{"issue":"25","key":"10.1016\/j.vhri.2026.101662_bib41","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes","volume":"372","author":"Cannon Christopher","year":"2015","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.vhri.2026.101662_bib42","doi-asserted-by":"crossref","first-page":"701","DOI":"10.46747\/cfp.6910701","article-title":"Lipid-lowering therapies for cardiovascular disease prevention and management in primary care","volume":"69","author":"Dugr\u00e9","year":"2023","journal-title":"Can Fam Physician"},{"issue":"22","key":"10.1016\/j.vhri.2026.101662_bib43","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"Schwartz Gregory","year":"2018","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.vhri.2026.101662_bib44","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1161\/ATVBAHA.119.313286","article-title":"Emerging mechanisms of cardiovascular protection for the omega-3 fatty acid eicosapentaenoic acid","volume":"40","author":"Mason","year":"2020","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.vhri.2026.101662_bib45","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ijcard.2022.11.031","article-title":"Effectiveness of statins for the primary prevention of cardiovascular disease in the Asian elderly population","volume":"373","author":"Lin","year":"2023","journal-title":"Int J Cardiol"},{"issue":"11","key":"10.1016\/j.vhri.2026.101662_bib46","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1001\/jamacardio.2019.3502","article-title":"Effect of 1 or 2 doses of inclisiran on low-density lipoprotein cholesterol levels: one-year follow-up of the ORION-1 randomized clinical trial","volume":"4","author":"Ray","year":"2019","journal-title":"JAMA Cardiol"},{"issue":"25","key":"10.1016\/j.vhri.2026.101662_bib47","first-page":"e1082","article-title":"AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice guidelines","volume":"139","author":"Grundy","year":"2018","journal-title":"J Am Coll Cardiol, 2019"},{"issue":"4","key":"10.1016\/j.vhri.2026.101662_bib48","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1007\/s40119-025-00438-0","article-title":"Real-world adherence and effectiveness of inclisiran in lowering LDL-C: results from 1 year of follow-up","volume":"14","author":"Ballantyne","year":"2025","journal-title":"Cardiol Ther"},{"issue":"17","key":"10.1016\/j.vhri.2026.101662_bib49","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1093\/eurheartj\/ehw046","article-title":"Percent reduction in LDL cholesterol following high-intensity statin therapy: potential implications for guidelines and for the prescription of emerging lipid-lowering agents","volume":"37","author":"Ridker","year":"2016","journal-title":"Eur Heart J"},{"issue":"18","key":"10.1016\/j.vhri.2026.101662_bib50","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine Marc","year":"2017","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.vhri.2026.101662_bib51","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1316222","article-title":"A 52-week placebo-controlled trial of evolocumab in hyperlipidemia","volume":"370","author":"Blom","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vhri.2026.101662_bib52","article-title":"The combination use of inclisiran and statins versus statins alone in the treatment of dyslipidemia in mainland China: a cost-effectiveness analysis","volume":"15","author":"Zhou","year":"2024","journal-title":"Front Pharmacol"}],"container-title":["Value in Health Regional Issues"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212109926000774?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212109926000774?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T09:15:41Z","timestamp":1789895741000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212109926000774"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2027,1]]},"references-count":50,"alternative-id":["S2212109926000774"],"URL":"https:\/\/doi.org\/10.1016\/j.vhri.2026.101662","relation":{},"ISSN":["2212-1099"],"issn-type":[{"value":"2212-1099","type":"print"}],"subject":[],"published":{"date-parts":[[2027,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Patient Preferences for Lipid-Lowering Agents in Hypercholesterolemia: A Discrete Choice Experiment","name":"articletitle","label":"Article Title"},{"value":"Value in Health Regional Issues","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vhri.2026.101662","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of International Society for Pharmacoeconomics and Outcomes Research, Inc.","name":"copyright","label":"Copyright"}],"article-number":"101662"}}